TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02680990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Band Together
Description: Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Education
Description: Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
Study: NCT03980808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: American Sign Language-Accessible Diabetes Education
Description: Video-based ASL interpreted diabetes educational intervention (ASL-ADE), the content of which will be derived from diabetes health information regarding symptoms and risk factors that are published by the U.S. Centers for Diseases Control and Prevention (CDC) and the National Institute for Health (NIH) National Diabetes Education Program.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Intervention
Description: Non-health related video approximately the same length as ASL-ADE.
Study: NCT03914638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol 4Mg Tablet
Description: Salbutamol 4 mg, three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo, three times daily
Study: NCT01249027

Intervention type: DEVICE
Intervention: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Description: Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
Study: NCT03014011

Intervention type: OTHER
Group type: OTHER
Intervention: Hypoglycaemic clamp
Description: The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Hypoglycaemic clamp
Description: The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Euglycaemic clamp
Description: The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.
Study: NCT01203696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: For patient with suboptimal angina control: oral 2.5-10mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: For patient with suboptimal BP control: 2.5-10mg daily po
Study: NCT02253264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT04764045

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
Study: NCT02646085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11 Methionine positron emission tomography
Description: diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
Study: NCT03922685

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary manipulation (25% carbohydrate diet) and behavioral (exercise)
Description: The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. Exercise was walking 1 hour on level treadmill at 50% of maximal effort starting 40 minutes after the beginning of the meal

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary manipulation (25% carbohydrate diet) and behavioral (exercise)
Description: The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. Exercise was walking 1 hour on level treadmill at 50% of maximal effort starting 40 minutes after the beginning of the meal

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary manipulation (25% carbohydrate diet) and behavioral (sedentary)
Description: The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. There was no exercise during this trial.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary manipulation (25% carbohydrate diet) and behavioral (sedentary)
Description: The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. There was no exercise during this trial.
Study: NCT03539510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HF-ACP Website
Description: Each module is broken down into weekly topics and each module takes 3-6 weeks to complete. Participants can access and review the material as often as needed as well as revisiting the information from modules they have completed.
Study: NCT05840445

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Onabotulinum toxin A
Description: Intramuscular application of onabotulinum toxin-A in the upper facial third.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prabotulinumtoxin A
Description: Intramuscular application of prabotulinum toxin-A in the upper facial third.
Study: NCT03014011

Intervention type: OTHER
Group type: OTHER
Intervention: Euglycaemic clamp
Description: The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.
Study: NCT02679846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized protocol
Description: The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
Study: NCT03635723

Intervention type: DEVICE
Intervention: Activity monitor
Description: Technology allowing measurement of physical activity
Study: NCT01113099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Academic detailing
Description: Education of physicians by pharmacists regarding indications for statins in diabetic patients
Study: NCT03761316

Intervention type: OTHER
Intervention: interview regarding goals
Description: interview regarding goals
Study: NCT03189459

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Visit Program
Description: RC: Informed consent discussion, documentation RN: UPDRS I-II, vitals, medication reconciliation, patient medical history and comorbidities RN and SW: Home safety assessment SW: Psychosocial assessment of dyad, HADS, assessment of mobility and homebound status, needs assessment of dyad, caregiver medical history and comorbidities RC: patient and caregiver short MoCA, PD-Rx, health literacy assessment, satisfaction surveys; patient PDQ-39/PDQ-8

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Visit Program
Description: RC: Informed consent discussion, documentation RN: UPDRS I-II, vitals, medication reconciliation, patient medical history and comorbidities RN and SW: Home safety assessment SW: Psychosocial assessment of dyad, HADS, assessment of mobility and homebound status, needs assessment of dyad, caregiver medical history and comorbidities RC: patient and caregiver short MoCA, PD-Rx, health literacy assessment, satisfaction surveys; patient PDQ-39/PDQ-8

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Mentorship Program
Description: Both mentors and mentees will be completing this program:~Mentors will be asked to complete: 1) a Mentor Training - One 5-hour session at Rush University Medical Center; and 2) two 16-week periods of mentoring someone who is currently a caregiver for a patient with Parkinson's Disease~Caregivers mentees will be asked to complete a 16 week mentorship program with their assigned mentor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Mentorship Program
Description: Both mentors and mentees will be completing this program:~Mentors will be asked to complete: 1) a Mentor Training - One 5-hour session at Rush University Medical Center; and 2) two 16-week periods of mentoring someone who is currently a caregiver for a patient with Parkinson's Disease~Caregivers mentees will be asked to complete a 16 week mentorship program with their assigned mentor
Study: NCT04278859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
Study: NCT01756378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: joint mobilization with movement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program
Description: I.R, stretching exercises, strengthen exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program
Description: I.R, stretching exercises, strengthen exercises
Study: NCT01215201

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scaling and Root Planing
Description: Use periodontal hand instruments (curettes) to remove plaque, bacteria, and deposits on the root's surfaces.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser + Scaling and Root Planing
Description: First: Periodontal hand instruments (curettes) were used to remove plaque, bacteria, and deposits on the root's surfaces (within a periodontal pocket) Then: Biolase 940 nm Ezlase diode laser was used to sterilize a periodontal pocket. Power: 0.80 Watts Wavelength: 940 nm Energy level: 0.80 Joules/second Mode of beam delivery: continuous
Study: NCT01576614

Intervention type: BEHAVIORAL
Intervention: Remote physician rounding
Description: Use of Remote physician rounding using Remote Telepresence Robotics

Intervention type: BEHAVIORAL
Intervention: Remote physician rounding
Description: Use of Remote physician rounding using Remote Telepresence Robotics
Study: NCT00924898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz, emtricitabine, and tenofovir
Description: Once daily ART with emtricitabine, tenofovir DF and efavirenz
Study: NCT04447729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fremanezumab
Description: Two doses, each dose consists of 4 injections with prefilled syringes
Study: NCT01635088

Intervention type: DRUG
Group type: OTHER
Intervention: Mometasone furoate 220
Description: dry powder inhaler QD for 28-43 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KoKo Spirometry

Intervention type: DRUG
Group type: OTHER
Intervention: Mometasone furoate 440
Description: dry powder inhaler QD for 28-43 days
Study: NCT04642313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium and/ or Potassium
Description: Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium and/ or Potassium
Description: Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium and/ or Potassium
Description: Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium and/ or Potassium
Description: Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia
Study: NCT00922753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VS
Description: Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
Study: NCT01635088

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oscillometry
Study: NCT04386785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) Thermal Ablation of Incompetent Perforator Veins
Description: The physician operator will access the IPV and advance the device to the target treatment position using ultrasound guidance. After providing local anesthesia to the vein and surrounding tissues, thermal ablation energy is delivered to the vein wall. After treatment is complete, the device is removed and vessel closure confirmed with duplex ultrasound.
Study: NCT00922753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AI-4/PEEP-4
Description: Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
Study: NCT04400994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab would be given intravenously.~* IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~* Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~* If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~* Maximum infusion rate is 400 mg/hr (400 ml/hr)~* Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~* Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab would be given intravenously.~* IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~* Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~* If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~* Maximum infusion rate is 400 mg/hr (400 ml/hr)~* Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~* Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVIg
Description: IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg:~0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min \& beyond: 180ml/hour
Study: NCT01824017

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draw
Study: NCT05302011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg i.v. day 1-22-43-64

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin or Cisplatin
Description: Carboplatin Area Under the Curve(AUC) = 4-5 i.v. day 1-22-43-64 or Cisplatin 75mg/m2 i.v. day 1-22-43-64

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 i.v. day 1-22-43-64
Study: NCT01052948

Intervention type: OTHER
Intervention: Retrospective study-

Intervention type: OTHER
Intervention: Retrospective study-

Intervention type: OTHER
Intervention: Retrospective study-

Intervention type: OTHER
Intervention: Retrospective study-
Study: NCT02153918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V/TRICOM
Description: A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F/TRICOM
Description: A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
Study: NCT05646914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex training exercises
Description: Squats and drop jumps, Barbell step-ups and hops, Bench press and plyometric press-up, Barbell lunge and box jumps were performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric training exercises
Description: Drop Jumps, Hops, Plyometric press-up, Box Jumps were performed.
Study: NCT03747471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetic Conversation Map
Description: Diabetic Conversation Map education tools are a series of tools for facilitated group education 5-8that were developed by Healthy Interactions in collaboration with the International Diabetes Federation (IDF) and are sponsored by Lilly Diabetes.~CM-based education guides people with diabetes through a process with the aim of helping them understand and internalize information about their disease and generate insightful conclusions, which may then result in improved self-management decisions and actions.
Study: NCT00914069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIVS vascular access
Description: Access to peripheral vasculature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vascular access
Description: Vascular access using conventional venous access device
Study: NCT02029417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omacetaxine mepesuccinate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00639509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo contrast-enhanced computed tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contrast-enhanced magnetic resonance imaging
Description: Undergo contrast-enhanced magnetic resonance imaging
Study: NCT05442658

Intervention type: OTHER
Intervention: Microbiota

Intervention type: OTHER
Intervention: Microbiota
Study: NCT04529694

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Study: NCT04113135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants will be lead through a series of yoga poses by a licensed physical therapist with advanced training in yoga. Participants in this group will also receive education related to MS as well as SMART goal setting, journaling and guided meditation. Modifications will be offered as needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group will receive education related to MS as well as SMART goal setting, journaling, and guided meditation.
Study: NCT03580018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Powder
Description: Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Post-anterior cruciate ligament reconstruction (ACLR)
Description: Post-anterior cruciate ligament reconstruction (ACLR)
Study: NCT03168945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GeneXpert MTB/RIF
Description: Screening intervention: novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB collected and performed at point-of-contact in a mobile van

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smear microscopy
Description: Screening intervention: routine diagnostic test (smear microscopy) for active case finding for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
Study: NCT02406820

Intervention type: DEVICE
Intervention: Non-invasive hemodynamic monitoring (CVInsight™ [CVI])

Intervention type: DEVICE
Intervention: Non-invasive hemodynamic monitoring (CVInsight™ [CVI])

Intervention type: DEVICE
Intervention: Non-invasive hemodynamic monitoring (CVInsight™ [CVI])
Study: NCT03424135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride soft capsules
Description: Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride soft capsules
Description: Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)
Description: Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)
Description: Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
Study: NCT03578042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan and amlodipine and hydrochlorothiazide
Description: this is a fixed combination containing the 3 drugs
Study: NCT00922753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AI-6/PEEP-4
Description: Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
Study: NCT03223662

Intervention type: OTHER
Group type: OTHER
Intervention: Chemoradiotherapy
Description: Chemotherapy: Carboplatin (AUC=2)x5 and Paclitaxel (50 mg/m(2))x5 for two cycles. Radiation: a total dose of 40.4 Gray (Gy) will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.